Literature DB >> 30921785

Predicting VMAT patient-specific QA results using a support vector classifier trained on treatment plan characteristics and linac QC metrics.

Dal A Granville1, Justin G Sutherland, Jason G Belec, Daniel J La Russa.   

Abstract

The use of treatment plan characteristics to predict patient-specific quality assurance (QA) measurement results has recently been reported as a strategy to help facilitate automated pre-treatment verification workflows or to provide a virtual assessment of delivery quality. The goal of this work is to investigate the potential of using treatment plan characteristics and linac performance metrics (i.e. quality control test results) in combination with machine learning techniques to predict the results of VMAT patient-specific QA measurements. Using features that describe treatment plan complexity and linac performance metrics, we trained a linear support vector classifier (SVC) to classify the results of VMAT patient-specific QA measurements. The 'targets' in this model were simple classes representing median dose difference between measured and expected dose distributions-'hot' if the median dose deviation was  >1%, 'cold' if it was  <-1%, and 'normal' if it was within  ±1%. A total of 1620 unique patient-specific QA measurements were available for model development and testing. 75% of the data were used to develop and cross-validate the model, and the remaining 25% were used for an independent assessment of model performance. For the model development phase, a recursive feature elimination (RFE) cross-validation technique was used to eliminate unimportant features. Model performance was assessed using receiver operator characteristic (ROC) curve metrics. Of the ten features found to be most predictive of patient-specific QA measurement results, half were derived from treatment plan characteristics and half from quality control (QC) metrics characterizing linac performance. The model achieved a micro-averaged area under the ROC curve of 0.93, and a macro-averaged area under the ROC curve of 0.88. This work demonstrates the potential of using both treatment plan characteristics and routine linac QC results in the development of machine learning models for VMAT patient-specific QA measurements.

Entities:  

Mesh:

Year:  2019        PMID: 30921785     DOI: 10.1088/1361-6560/ab142e

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  5 in total

1.  Auto-Trending daily quality assurance program for a pencil beam scanning proton system aligned with TG 224.

Authors:  Chengyu Shi; Qing Chen; Francis Yu; Jingqiao Zhang; Minglei Kang; Shikui Tang; Chang Chang; Haibo Lin
Journal:  J Appl Clin Med Phys       Date:  2020-12-18       Impact factor: 2.102

2.  Predicting gamma evaluation results of patient-specific head and neck volumetric-modulated arc therapy quality assurance based on multileaf collimator patterns and fluence map features: A feasibility study.

Authors:  Sangutid Thongsawad; Somyot Srisatit; Todsaporn Fuangrod
Journal:  J Appl Clin Med Phys       Date:  2022-05-18       Impact factor: 2.243

3.  Deep Learning for Patient-Specific Quality Assurance: Predicting Gamma Passing Rates for IMRT Based on Delivery Fluence Informed by log Files.

Authors:  Ying Huang; Yifei Pi; Kui Ma; Xiaojuan Miao; Sichao Fu; Zhen Zhu; Yifan Cheng; Zhepei Zhang; Hua Chen; Hao Wang; Hengle Gu; Yan Shao; Yanhua Duan; Aihui Feng; Weihai Zhuo; Zhiyong Xu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  Commissioning and clinical implementation of an Autoencoder based Classification-Regression model for VMAT patient-specific QA in a multi-institution scenario.

Authors:  Ruijie Yang; Xueying Yang; Le Wang; Dingjie Li; Yuexin Guo; Ying Li; Yumin Guan; Xiangyang Wu; Shouping Xu; Shuming Zhang; Maria F Chan; Lisheng Geng; Jing Sui
Journal:  Radiother Oncol       Date:  2021-06-21       Impact factor: 6.901

Review 5.  Integration of AI and Machine Learning in Radiotherapy QA.

Authors:  Maria F Chan; Alon Witztum; Gilmer Valdes
Journal:  Front Artif Intell       Date:  2020-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.